Opportunities for brick-and-mortar retailers
With e-commerce capturing a growing slice of the retail pie, the future of the physical store becomes a more urgent question.
With e-commerce capturing a growing slice of the retail pie, the future of the physical store becomes a more urgent question.
President Trump has unveiled the administration’s much anticipated plan to reduce pharmaceutical prices.
Kroger Co. has upped its investment in U.K. digital grocer Ocado as part of an exclusive agreement that will bring Ocado’s automated fulfillment network to the United States to bolster Kroger’s home delivery capabilities.
As the epidemic of opioid abuse continues to escalate in America, corporations and other organizations are ramping up their efforts to fight the problem. Rite Aid Corp.
Two CVS Health executives were in the spotlight last month at events discussing the new challenges facing the health care industry.
Discount Drug Mart and McKesson High Volume Solutions (HVS) have entered into a pharmacy automation agreement that calls for McKesson HVS to provide the retail pharmacy operator with a dispensing automation platform for a central fill pharmacy in Avon Lake, Ohio.
Albertsons Cos. and Rite Aid Corp. hosted a joint analyst event last month to discuss the strategic and financial benefits of the proposed merger transaction between the two companies.
The board of directors of Diplomat Pharmacy has appointed Brian Griffin board chairman and chief executive officer, effective June 4, the company announced last month. Griffin recently resigned as the executive vice president and CEO of IngenioRx, the pharmacy benefit manager of Anthem Inc.
Walgreens Boots Alliance executive vice chairman and chief executive officer Stefano Pessina urged analysts not to think they can see the future of Walgreens simply by visiting the company’s new pilot stores in Gainesville, Fla.
Chain drug retailers reacted favorably to President Trump’s drug price cutting plan; branded pharmaceutical manufacturers less so.
The White House last month steered clear of extreme measures in issuing a plan to cut drug prices. While President Donald Trump called the proposal “the most sweeping action in history to lower the price of prescription drugs for the American people,” the plan left industry stakeholders relieved.